J Clin Oncol 2021 Aug 03
Adjuvant PARP Inhibitors in Patients With High-Risk Early-Stage HER2-Negative Breast Cancer and Germline Mutations: ASCO Hereditary Breast Cancer Guideline Rapid Recommendation Update.
ABSTRACT
Related Questions
Definitions for "high risk" differ by whether patients receive neoadjuvant chemo and across other contemporary studies. Does the change in AJCC stagin...
New comment by Medical Oncologist at Colorado Permanente Medical Group Hematology & Oncology ( June 9, 2022)
Do you feel this is a reason to give NAC to T1cNo TNBC who are known to be gBRCAm+? As this will enable you to give adjuvant olaparib for those who do not have a pCR? Since if...